NCT01443663View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2013

Conditions

H5N1 Influenza

Interventions

BIOLOGICAL

H5N1 Vaccine

Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.

Trial Locations (1)

21205

Centers for Immunization Research (CIR) - John Hopkins Bloomburg School of Public Health, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01443663 - Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine | Biotech Hunter | Biotech Hunter